JPRN-jRCT2080225280已完成3 期
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
ovartis Pharma. K.K.0 个研究点目标入组 7,680 人开始时间: 2020年7月17日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7,680
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Lp(a) =>70 mg/dL at the screening visit, measured at the Central laboratory
- •Myocardial infarction: >= 3 months from screening and randomization to =< 10 years prior to the screening visit
- •Ischemic stroke: =>3 months from screening and randomization to =< 10 years prior to the screening visit
- •Clinically significant symptomatic peripheral artery disease
排除标准
- •Uncontrolled hypertension
- •Heart failure New York Heart Association (NYHA) class IV
- •History of malignancy of any organ system
- •History of hemorrhagic stroke or other major bleeding
- •Platelet count=Active liver disease or hepatic dysfunction
- •Significant kidney disease
- •Pregnant or nursing women
研究者
相似试验
进行中（未招募）
不适用
A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer - MENZABrain metastastases of non-small or small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10050017Term: Lung cancer metastaticEUCTR2006-000889-36-PLEli Lilly and Company108
进行中（未招募）
不适用
A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer - N/AEUCTR2006-000889-36-SEEli Lilly and Company limited108
进行中（未招募）
不适用
A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer - N/AEUCTR2006-000889-36-FIEli Lilly and Company limited108
进行中（未招募）
不适用
A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer - N/Abrain metastastases of non-small or small cell lung cancerEUCTR2006-000889-36-DKEli Lilly and Company limited108
Unknown
3 期
Placebo Versus SBR759 in Lowering Phosphate in Dialysis PatientsCTRI/2010/091/000298ovartis290